Friday, November 05, 2021 – 06:45am
PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
Focus on Cross Border Integration of Biomedicine and Chemical Materials: New Opportunities, New Technologies and New Models
This forum focuses on the interdisciplinary and cutting-edge technologies...
Pfizer is seeking emergency use authorisation from the FDA for its novel Covid-19 antiviral pill Paxlovid.
Share Article
On the heels of Merck antiviral molnupiravir’s UK approval, Pfizer...
The 3rd CMC-China 2021
Time: September 29-30, 2021
Exhibition Venue: C-D Hall, Suzhou International Expo Center, Suzhou City, JIangsu Province, China.
Synergy of Centralized China’s Drug Volume-ba...
The third Guangdong-Hong Kong-Macao Greater Bay Area Pharmaceutical Innovation Technology and Market Access Summit forum November 19 to 21, 2021
As the world’s second largest medical market, ...